2DG Dendrimer Neuron Targeting Across the Blood-Brain Barrier
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Delivering therapeutic molecules across the blood-brain barrier (BBB) is challenging, particularly for targeting neurons at the site of brain injury, as most drugs fail to penetrate this barrier, and existing nanocarriers lack specificity and efficacy for neuronal delivery, leading to limited therapeutic outcomes in neurological disorders.
Innovation Solution
A 2-deoxyglucose (2DG) surfaced dendrimer conjugated with neuroactive agents and imaging agents is designed to target neurons via GLUT transporters, utilizing robust chemical linkages to prevent degradation and enhance renal excretion, ensuring precise delivery and imaging.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional drugs are administered systemically, then they can reach the bloodstream, but they fail to penetrate the blood-brain barrier and reach neurons at the injury site
Solution Approach 1:
The patent uses a dendrimer nanocarrier as an intermediary vehicle to transport neuroactive agents across the blood-brain barrier. The dendrimer's surface-modified structure with targeting ligands enables it to interact with and traverse the BBB, delivering the therapeutic payload to neurons that would otherwise be inaccessible to conventional drugs
Solution Approach 2:
The patent modifies the physical and chemical parameters of the drug delivery system by using nanoscale dendrimers with specific surface modifications. These parameter changes enable the system to penetrate the blood-brain barrier through enhanced permeability and active targeting mechanisms, overcoming the barrier that blocks conventional molecular-sized drugs
2Reliability
If existing nanocarriers are used for brain drug delivery, then they can cross the blood-brain barrier, but they lack specificity for neuronal targeting
Solution Approach 1:
The patent applies local quality by modifying only the surface of the dendrimer nanocarrier with specific targeting ligands while maintaining the core structure. This localized modification provides neuronal specificity without requiring complete redesign of the entire nanocarrier system, balancing targeting capability with manufacturing feasibility
Solution Approach 2:
The patent creates a composite nanocarrier system combining dendrimer core structure with surface-grafted targeting ligands. This composite approach integrates the advantages of both components: the dendrimer provides stable drug carrying capacity while the surface ligands provide neuronal specificity, achieving enhanced targeting without excessive manufacturing complexity
3Quantity of substance
If drugs are delivered systemically to treat brain injury, then they can be administered non-invasively, but they cannot achieve sufficient concentration at the specific disease site
Solution Approach 1:
The dendrimer nanocarrier acts as a mediator that concentrates the therapeutic payload at the target site through active targeting. The surface-modified dendrimer binds to neuronal receptors, facilitating endocytosis and intracellular release, thereby achieving high local drug concentrations through systemic administration without requiring invasive delivery methods
Solution Approach 2:
The patent changes the pharmacokinetic parameters of the drug by encapsulating it within dendrimers that exhibit enhanced stability, prolonged circulation time, and active targeting capabilities. These parameter changes enable the drug to accumulate at the brain injury site through the EPR effect and receptor-mediated transcytosis, achieving therapeutic concentrations via non-invasive systemic injection
4Reliability
If 2-deoxyglucose is used for neuron targeting via GLUT transporters, then specific neuronal delivery is achieved, but there is risk of deleterious effects in injured brain regions
Solution Approach 1:
The patent extracts only the targeting function of 2-deoxyglucose by using it solely as a surface ligand on the dendrimer nanocarrier rather than as the therapeutic payload itself. This separation allows the dendrimer to exploit GLUT transporter-mediated uptake for precise neuronal targeting while the actual therapeutic agent remains a separate, non-toxic neuroactive compound
Solution Approach 2:
The dendrimer structure serves as an intermediary between the 2-deoxyglucose targeting ligand and the neuroactive therapeutic payload. This intermediary architecture enables the system to utilize the GLUT transporter recognition capability of 2DG while protecting injured neurons from its potentially harmful metabolic effects, as the 2DG remains bound to the dendrimer surface and does not enter the cell in free form
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The 2DG dendrimer effectively targets neurons at the site of brain injury, enhancing drug delivery and imaging capabilities while minimizing systemic side effects and improving therapeutic outcomes in neurological conditions.
Implementation Method 1
2DG is incorporated at the surface of 2DG-D to achieve neuron targeting via GLUT transporters
Data Source
AI summary
Provided herein is a dendrimer complex comprising a 2-deoxyglucose (2DG) dendrimer and a neuroactive agent conjugated to an outer surface of the dendrimer. The dendrimer complex may further include one or more imaging agents and/or radioligands conjugated to an outer surface of the dendrimer. Such complexes are useful in methods for detecting or treating neurological diseases or disorders.